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Maintenance of telomeres, repetitive elements at eukaryotic chromosomal termini, and
the end-capping structure and function they provide, are imperative for preserving genome
integrity and stability. The discovery that telomeres are transcribed into telomere repeat
containing RNA (TERRA) has revolutionized our view of this repetitive, rather unappre-
ciated region of the genome. We have previously shown that the non-homologous end-
joining, shelterin associated DNA dependent protein kinase catalytic subunit (DNA-PKcs)
participates in mammalian telomeric end-capping, exclusively at telomeres created by
leading-strand synthesis. Here, we explore potential roles of DNA-PKcs and its phosphory-
lation target heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) in the localization
of TERRA at human telomeres. Evaluation of co-localized foci utilizing RNA-FISH and
three-dimensional (3D) reconstruction strategies provided evidence that both inhibition
of DNA-PKcs kinase activity and siRNA depletion of hnRNP A1 result in accumulation of
TERRA at individual telomeres; depletion of hnRNP A1 also resulted in increased frequen-
cies of fragile telomeres.These observations are consistent with previous demonstrations
that decreased levels of the nonsense RNA-mediated decay factors SMG1 and UPF1
increase TERRA at telomeres and interfere with replication of leading-strand telomeres.
We propose that hTR mediated stimulation of DNA-PKcs and subsequent phosphorylation
of hnRNP A1 influences the cell cycle dependent distribution of TERRA at telomeres by
contributing to the removal ofTERRA from telomeres, an action important for progression
of S-phase, and thereby facilitating efficient telomere replication and end-capping.
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INTRODUCTION
Telomeres are highly conserved tandem arrays of repetitive DNA
sequence, TTAGGG in vertebrates (Meyne et al., 1989), that serve
to protect the physical ends of linear chromosomes and prevent
their detection as broken DNA, thereby evading an inappropriate
damage response (de Lange, 2009). Adult human telomeres range
in length from∼5 to 15 kb and end with a 3′ single-stranded G-rich
overhang of ∼12–300 nucleotides (Makarov et al., 1997; Wright
et al., 1997; Zhao et al., 2008), a key feature for end-protection
and extension. The telomeric single-stranded overhang can invade
homologous double-stranded telomere tracks to create a telomere
loop (t-loop) structure (Griffith et al., 1999). T-loop formation is
facilitated by a complex of telomere-bound and associated pro-
teins termed shelterin (de Lange, 2005; Palm and de Lange, 2008)
that act together to sequester these natural DNA ends (reviewed
in Martinez and Blasco, 2011). The G-rich single-stranded telom-
eric DNA is also subject to G-quadruplex formation (Parkinson
et al., 2002), another structural solution that may contribute
to end-protection. During development and later in some cell
types including cancer and stem cells, the single-stranded G-
rich overhang also provides the substrate required for elongation
by telomerase, the specialized ribonucleoprotein (RNP) possess-
ing reverse transcriptase activity (TERT) capable of catalyzing de
novo telomere repeat addition utilizing an internal RNA template
(TR) complementary to the telomeric DNA sequence (Greider and
Blackburn, 1985, 1989).
As a consequence of residing at chromosomal termini, telom-
eres must also negotiate the “end-replication problem,” an issue
resulting from the inherent inability of conventional DNA poly-
merases to replicate the extreme end of linear DNA (Olovnikov,
1971; Watson, 1972). In telomerase-negative human cells, the
rate of telomere shortening is estimated to be ∼50–100 base
pairs per cell division (Zhao et al., 2008). Telomeres synthesized
by leading-strand semiconservative DNA replication are initially
blunt-ended and so are not shortened compared to their parental
DNA template. In contrast, newly replicated lagging-strand telom-
eres possess overhangs at the onset due to their requirement
for an RNA primer, and therefore begin life shorter than their
parental template, the degree of shortening being dependent on
the position and removal of the terminal RNA primer (Chow
et al., 2012). After processing to generate mature single-stranded 3′
overhangs, lagging-strand overhangs are ∼threefold longer than
leading-strand overhangs (Zhao et al., 2008; Chow et al., 2012),
the consequence being telomere shortening with each round of
replication. Once telomeres become critically short, a state of irre-
versible cell cycle arrest known as cellular senescence is entered
(Harley et al., 1990). The vast majority of cancer cells overcome
this effective tumor suppressor barrier by re-activating telomerase
www.frontiersin.org April 2013 | Volume 3 | Article 91 | 1
Le et al. TERRA, hnRNP A1, DNA-PKcs, and telomeres
(Kim et al., 1994), which adds ∼60 nucleotides to most chromo-
some ends (Zhao et al., 2009). Those tumors that do not express
telomerase maintain telomere length via a recombination-based
mechanism termed alternative lengthening of telomeres (ALT)
(Murnane et al., 1994; Bryan et al., 1997; Dunham et al., 2000). In
addition to tumor cells, telomerase has been shown to be active
in germ line and stem cells, but is not present at sufficient lev-
els in somatic cells to maintain telomere length (Kim et al., 1994;
Mantell and Greider, 1994; Chiu et al., 1996; Hiyama et al., 1996;
Wright et al., 1996).
Telomeres and their plethora of interacting partners must
also create an environment refractory to DNA repair in order to
maintain genomic stability (reviewed in O’Sullivan and Karlseder,
2010). Recent studies have demonstrated that telomeres and adja-
cent sub-telomeric regions (to ∼100 kb) are sensitive to double-
strand breaks (DSBs) due to being deficient in their repair by non-
homologous end-joining (NHEJ) (Kulkarni et al., 2010; Miller
et al., 2011), and further that persistent DSBs near telomeres in
normal cells, both in vitro and in vivo, contribute to aging and ion-
izing radiation-induced senescence (Fumagalli et al., 2012; Hewitt
et al., 2012). The sensitivity of telomeric regions to unrepaired
DSBs has also been proposed as an important contributor to
chromosome instability in human cancer (Muraki et al., 2012).
Nonetheless, the cell’s repair machinery has also been shown to
be essential for telomere function. One such example is the NHEJ,
shelterin associated DNA dependent protein kinase catalytic sub-
unit (DNA-PKcs) that participates in mammalian telomeric end-
capping, particularly at telomeres created by leading-strand syn-
thesis (Bailey et al., 1999, 2001). Characterization of telomere dys-
function in DNA-PKcs deficient backgrounds provided evidence
that DNA-PKcs kinase activity is critical (Bailey et al., 2004b), and
further that autophosphorylation of Prkdc at the Threonine-2609
cluster (and not the Serine-2056 cluster) represents an important
in vivo DNA-PKcs target at telomeres (Williams et al., 2009). Addi-
tionally, uncapped telomeres in such repair deficient backgrounds
co-localized with γ-H2AX forming telomere dysfunction-induced
foci (TIFs) (Takai et al., 2003), supporting their detection as DSBs
and inappropriate triggering of a DNA damage response. It is also
the case that many of the proposed mechanisms for generating 3′
single-stranded telomeric overhangs implicate DNA damage sig-
naling and associated repair factors (Denchi and de Lange, 2007;
Li et al., 2009). The SNMIB/Apollo 5′-to-3′ exonuclease that binds
the shelterin component TRF2 (Freibaum and Counter, 2008),
provides an interesting example in that it has been shown to be
required for appropriate resection and formation of 3′ overhangs
at leading-, but not lagging-strand telomeres, thereby protecting
them from engaging the NHEJ pathway (Lam et al., 2010; Wu et al.,
2012).
DNA-PKcs is a member of the phosphoinositide-3-kinase like
kinase (PIKK) family that in humans also consists of ataxia
telangiectasia-mutated (ATM),ATM/rad3-related (ATR), suppres-
sor with morphogenetic effect on genitalia-1 (SMG1), mammalian
target of rapamycin (mTOR), and transformation/transcription
domain associated protein (TRRAP), many of which have been
implicated in telomere function. For example, SMG factors
have been shown to bind human telomeres and their depletion
induces telomeric aberrations, including loss of telomeres and
accumulation of telomeric RNA at telomeres (Azzalin et al., 2007).
Importantly, SMG1 functions in the nonsense RNA-mediated
decay (NMD) pathway via phosphorylation of the telomere asso-
ciated eukaryotic helicase up-frameshift 1 (UPF1) (Yamashita
et al., 2001; Azzalin et al., 2007; Isken and Maquat, 2008; Chawla
et al., 2011). UPF1 is a downstream effector of SMG1 that can
be activated by other PIKKs as well, including DNA-PKcs and
ATR (Brumbaugh et al., 2004; Azzalin and Lingner, 2006; Muller
et al., 2007), and is required for S-phase progression and genome
stability (Azzalin and Lingner, 2006).
The majority of mammalian repetitive telomeric DNA is tightly
packaged into nucleosomes (Pisano et al., 2008) and carries
epigenetic marks characteristic of constitutive heterochromatin
(reviewed in Schoeftner and Blasco, 2009). Telomeres therefore,
have suffered from the misconception of being “junk” DNA and
had certainly long been considered transcriptionally silent. How-
ever, telomeres from a variety of species including mammalian, are
indeed transcribed into heterogeneous, non-coding transcripts,
or telomere repeat containing RNA termed TERRA (Azzalin and
Lingner, 2008; Schoeftner and Blasco, 2008). Chromatin bound
TERRA specifically localizes at telomeres and exists predominantly
as UUAGGG transcripts, thus are transcribed primarily from
telomere C-rich/leading parental strands (Azzalin et al., 2007),
that average around 200 bases in length (Porro et al., 2010). RNA-
DNA hybrids of TERRA with telomeric DNA have been proposed
(Luke et al., 2008). Telomeric G-rich RNA has been shown to form
G-quartets (Randall and Griffith, 2009), and in vitro structural
studies have demonstrated that telomeric RNA can specifically
associate with telomeric DNA via formation of hybrid parallel G-
quadruplex structures (Xu et al., 2008). Investigation of human
TERRA RNA in living cells has provided the first in vivo evidence
that TERRA RNA G-quadruplexes can localize to telomeres (Xu
et al., 2010). A variety of functions have been proposed for TERRA,
including regulation of telomerase activity, an appealing possi-
bility as TERRA presumably duplexes with the complementary
telomerase RNA template, hTR (Azzalin et al., 2007; Schoeftner
and Blasco, 2008). However, the view that TERRA acts to inhibit
telomerase has recently been challenged by the demonstration
that telomere length is maintained independently of TERRA and
highly transcribing telomeres (Farnung et al., 2012). TERRA, like
other non-coding RNAs, may facilitate telomeric heterochromatin
formation through its interactions with the shelterin component
Telomere Repeat Factor 2 (TRF2), as well as with other proteins
that facilitate heterochromatin formation, including the origin of
recognition complex (ORC) and heterochromatin protein 1 (HP1)
(Deng et al., 2009). TERRA interactions have also been proposed
to promote telomere replication (Feuerhahn et al., 2010), par-
ticularly at leading-strand telomeres (Chawla et al., 2011), and
facilitate end-capping function (Flynn et al., 2011).
Relatively little is known regarding the transcriptional regu-
lation of TERRA, although it is it at least partially transcribed by
RNA polymerase II (RNAPII) initiating at sub-telomeric CpG-rich
promoters, and shelterin components appear to play key roles in
regulating the process (Azzalin et al., 2007; Schoeftner and Blasco,
2008; Nergadze et al., 2009; Caslini, 2010). TERRA levels vary
through the cell cycle, being lowest in late S-phase and peaking
in early G1 (Porro et al., 2010), and TERRA can regulate its own
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transcription dependent on telomere length (Arnoult et al., 2012).
TERRA repression in human cells is dependent on chromatin sta-
tus of the telomeric region, as well as the nonsense mediated RNA
decay (NMD) pathway, whose actions are restricted to the cyto-
plasm (Singh et al., 2007). Depletion of the NMD factors SMG1
and UPF1 resulted in the dramatic accumulation of telomere-
bound TERRA, while total TERRA levels and turnover rate were
not affected (Azzalin et al., 2007). Further, efficient replication of
leading-strand telomeres has been shown to require human UPF1
(Chawla et al., 2011), as depletion of UPF1 resulted in fragile
telomeres, a phenotype reflective of telomere replication associ-
ated defects (Sfeir et al., 2009), specifically involving leading-strand
telomeres. Such studies provide additional support for strand-
specific interactions at telomeres, as well as for telomere instability
resulting from improper removal of telomere-bound TERRA. In
human cells, poly(A) tails have been demonstrated on the fraction
of TERRA transcripts not associated with chromatin (i.e., “free”),
which contributed to their stability; TERRA transcripts associated
with chromatin (i.e., “bound”) did not possess poly(A) tails, find-
ings suggestive of distinct biological roles of free vs. bound TERRA
(Porro et al., 2010).
The RNA binding protein heterogenous ribonuclear protein
A1 (hnRNP A1) belongs to a large family of hnRNPs (A–U) (He
and Smith, 2009) that function in shuttling mature RNA into the
cytoplasm, and in mediating splice site selection during alter-
native splicing (Mayeda and Krainer, 1992; Martinez-Contreras
et al., 2007). hnRNP A1 has also been shown to bind telom-
eric sequences, promote telomerase activity, and telomere length
extension, as well as facilitate removal of replication protein A
(RPA) from single-stranded telomeric DNA and participate in
telomeric end-capping following replication (LaBranche et al.,
1998; Ford et al., 2002; Zhang et al., 2006; Flynn et al., 2011).
Other proposed functions of hnRNP A1 that may contribute to
telomere replication include its ability to unwind G-quadruplexes
(Zhang et al., 2006), and to interact with human telomerase
(LaBranche et al., 1998) and telomerase RNA (Fiset and Chabot,
2001). Together with the fact that the consensus binding site of
hnRNP A1 resembles TERRA (Burd and Dreyfuss, 1994), accumu-
lating studies support an important role for hnRNP A1 in telomere
RNA/TERRA function (de Silanes et al., 2010). Of particular inter-
est to us in this regard were the demonstrations of direct hnRNP
A1 phosphorylation by DNA-PKcs (Zhang et al., 2004), and of
stimulation of DNA-PKcs dependent hnRNP A1 phosphorylation
by hTR, the RNA template component of human telomerase; novel
phosphorylation sites on hnRNP A1 targeted by DNA-PKcs were
also identified (Ting et al., 2009).
Here, we interrogated potential roles of hTR stimulated DNA-
PKcs dependent phosphorylation of hnRNP A1 in human telom-
eric end-capping structure and function involving TERRA. Eval-
uation of co-localized foci utilizing RNA-Fluorescence In situ
Hybridization (FISH) and three-dimensional (3D) reconstruc-
tion strategies in conjunction with either inhibition of DNA-PKcs
kinase activity or siRNA depletion of hnRNP A1 in human cells,
revealed significant accumulation of TERRA at telomeres, which
corresponded with an increased frequency of fragile telomeres
(Sfeir et al., 2009) with reduced hnRNP A1. These results are con-
sistent with those reported for depletion of SMG1 (Azzalin et al.,
2007) and UPF1 (Chawla et al., 2011), and suggest that DNA-PKcs
phosphorylation of hnRNP A1 influences the cell cycle dependent
distribution of TERRA at telomeres. We propose that hTR/DNA-
PKcs and hnRNP A1 interactions at telomeres contribute to the
removal of chromatin bound TERRA, thereby facilitating efficient
replication of telomeres and effective end-capping.
RESULTS
DNA-PKcs DEPENDENT PHOSPHORYLATION OF hnRNP A1 IS
STIMULATED BY hTR IN HUMANMAMMARY EPITHELIAL CELL LINES
The hTR component of telomerase has previously been shown to
stimulate DNA-PKcs dependent, site-specific phosphorylation of
hnRNP A1 (Ting et al., 2009). To confirm DNA-PKcs dependent
phosphorylation of hnRNP A1 in MCF-10A (“normal”) and MCF-
7 (tumor) human mammary epithelial cell lines, we performed 32P
uptake experiments to evaluate overall hnRNP A1 phosphoryla-
tion following DNA-PKcs depletion (siRNA) or kinase inhibition
(NU7026). Consistent with our previous experience in other cell
lines (Zhang et al., 2005), DNA-PKcs mRNA levels were reduced
by 24–48 h and protein levels were maximally reduced at 72 h
following siRNA transfection in both cell lines (Figure 1A). Rel-
ative protein expression of DNA-PKcs following siRNA silencing
was comparable between MCF-10A and MCF-7 (1.66± 0.66 and
2.20+ 0.58 respectively), as determined from three independent
protein isolations and immunoblots (data not shown).
Phosphorylated hnRNP A1, quantified per sample as the ratio
of 32P signal to hnRNP A1 (i.e., in the same lane), decreased follow-
ing DNA-PKcs siRNA knock down or kinase inhibition in MCF-7,
indicating that hnRNP A1 is indeed an in vivo substrate for DNA-
PKcs phosphorylation (Figure 1B). Similarly, decreased hnRNP
A1 32P signal was also observed in MCF-10A following siRNA
depletion of DNA-PKcs, but no decrease in 32P signal follow-
ing DNA-PKcs kinase inhibition was observed. This result likely
reflects the hTR dependency of DNA-PKcs stimulation and sub-
sequent phosphorylation of hnRNP A1, in that MCF-10A has
significantly lower levels of telomerase and hTR than MCF-7
(Ramachandran et al., 2002; Ting et al., 2009); i.e., low levels of
DNA-PKcs kinase stimulation by hTR in MCF-10A, therefore little
effect of DNA-PKcs kinase inhibition on overall hnRNP A1 phos-
phorylation status. Additionally, because this assay reflects overall
hnRNP A1 phosphorylation status, a reduction in low levels of
DNA-PKcs dependent site-specific phosphorylation of hnRNP A1
may well be masked. Consistent with this view, decreased DNA-
PKcs protein levels (siRNA) did result in reduced hnRNP A1 32P
signal, indicating that hnRNP A1 is a substrate for DNA-PKcs
phosphorylation in MCF-10A, although it may not be particularly
robust due to the low levels of hTR. It is also possible that other
kinases targeting hnRNP A1 are affected by the loss of DNA-PKcs;
e.g., ATM (Peng et al., 2005).
TERRA CO-LOCALIZATION AT TELOMERES IS INFLUENCED BY
hTR/DNA-PKcs AND hnRNP A1 INTERACTIONS
To evaluate the hTR/DNA-PKcs and hnRNP A1 dependency of
TERRA co-localization to telomeres, we inhibited DNA-PKcs
kinase activity (NU7026) or depleted hnRNP A1 protein levels
(siRNA) in MCF-10A (low hTR) and MCF-7 (high hTR). Follow-
ing hnRNP A1 siRNA transfection, cells were harvested at various
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FIGURE 1 | DNA-PKcs dependent phosphorylation of hnRNP A1 in
MCF-10A and MCF-7. (A) DNA-PKcs siRNA knockdown. Real-time
quantitative PCR assessment of DNA-PKcs mRNA relative expression
from 24 to 120 h following transfection in mock (M), siRNA (S) treated
cells, and the housekeeping gene Transferrin Receptor (TFRC). DNA-PKcs
mRNA expression was normalized to TFRC levels in each sample and
found to be maximally decreased at 24–48 h. DNA-PKcs protein levels
were also assessed following siRNA transfection in mock (M), siRNA (S),
or untreated (UT) cells over an identical time course; DNA-PKcs protein
expression was normalized to the actin control. Optimal depletion of
DNA-PKcs protein levels was observed at 72 h for both cell lines. An
extended time course (to 240 h) monitored recovery of protein levels (not
shown). (B) Overall phosphorylation status of hnRNP A1. 32P uptake
experiments followed by immunoblotting demonstrated decreased hnRNP
A1 32P signal with DNA-PKcs depletion (siRNA) and kinase inhibition
(NU7026) in MCF-7, and following DNA-PKcs siRNA silencing in MCF-10A;
no decrease of hnRNP A1 32P signal with DNA-PKcs kinase inhibition in
MCF-10A was observed.
times from 24 to 228 h and hnRNP A1 protein levels monitored rel-
ative to β-tubulin by immunoblotting (Figure 2). Optimal hnRNP
A1 knockdown (∼90%) was achieved at 72 h for both cell lines.
A non-target (NT) oligonucleotide sequence was also included
to confirm minimal off-target effect of the siRNA knockdown;
average 16.6% decrease (range 5.5–27%) in MCF-10A and a 3.3%
decrease (range−3.6 to 6.7%) in MCF-7 was observed. Four inde-
pendent collections were performed and immunoblot analysis was
repeated twice per collection.
Three-dimensional (3D) reconstruction of TRF2 (telomeres;
red) and TERRA (RNA-FISH; green) foci was performed on
controls and following DNA-PKcs kinase inhibition (NU7026)
or hnRNP A1 siRNA depletion (Figure 3). Co-localization of
TRF2 and TERRA foci was microscopically evaluated based on
merged yellow signals (2D), then confirmed by 3D deconvolution
and reconstruction image analysis as a single focus sharing both
red and green fluorochrome radii. Only cells presenting obvious
TERRA foci, irrespective of intensity or number, were selected for
analysis. Considering that TERRA levels are cell cycle dependent,
being highest in G1 and diminishing into S-phase, and that the
number of telomere (TRF2) signals were monitored, the majority
of cells scored were presumed to be in G1 to early/mid S-phase,
when TERRA associates with telomeres (Porro et al., 2010), and
telomeres are widely distributed throughout the nucleus (Chuang
et al., 2004). Pearson’s, Overlap and Mander’s coefficients were
calculated to evaluate the degree of foci co-localization; values con-
firmed that the two molecules were in very close physical proximity
to one another.
In MCF-10A (Figure 4A), comparison of co-localized foci in
40 TERRA positive cells within each treatment group revealed that
both controls (DMSO and mock) had similar total numbers of co-
localized foci (944 and 957; average number co-localized foci/cell
24), and both treatments (NU and siRNA) resulted in similar, sig-
nificant increases compared to their respective controls (1147 and
1143; average number co-localized foci/cell 29). DNA-PKcs kinase
inhibition resulted in 22% more co-localized foci in treated vs.
DMSO controls, and hnRNP A1 siRNA depletion resulted in a
19% increase compared to the mock control; both increases were
statistically significant (p= 0.002 and 0.007 respectively).
In MCF-7 (Figure 4B), the tumorigenic counterpart to MCF-
10A, comparison of co-localized foci in 40 TERRA positive cells
within each group revealed no significant effect of either treat-
ment. The total number of co-localized foci decreased in DNA-
PKcs kinase inhibited cells (859; average number of co-localized
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FIGURE 2 | hnRNP A1 siRNA knockdown in MCF-10A and MCF-7.
Following hnRNP A1 siRNA transfection, cells were harvested at various
times (24–228 h) and hnRNP A1 protein levels evaluated (Western blot);
graphs represent hnRNP A1 levels normalized to β-tubulin. Optimal
knockdown of hnRNP A1 protein (∼90%) was achieved at 72 h for both cell
lines (n=4, each examined with two immunoblot analyses).
foci/cell 21) compared to DMSO control (962; average num-
ber of co-localized foci/cell 24), but was not statistically signifi-
cant (p= 0.1352). Similarly, the total number of co-localized foci
increased in the hnRNP A1 siRNA depleted cells (1149; aver-
age number co-localized foci/cell 29) compared to mock control
(1084; average number co-localized foci/cell 27), but was not
significant (p= 0.3429).
TOTAL TERRA FOCI ARE INFLUENCED BY hTR/DNA-PKcs AND hnRNP A1
INTERACTIONS
Analysis of individual TERRA foci utilizing 3D reconstruction
strategies revealed that DNA-PKcs kinase inhibition (NU7026)
and depletion of hnRNP A1 (siRNA) significantly increased the
total number of TERRA foci (co-localized/bound and free) com-
pared to their respective DMSO or mock controls in both MCF-
10A (Figure 5A) and MCF-7 cell lines (Figure 5B). Inhibition of
DNA-PKcs kinase activity (NU) in MCF-10A resulted in a sig-
nificant increase of TERRA foci over the DMSO control: total
number of foci increased from 1975 to 2237; average foci per cell
increased from 49 to 56 (p= 0.002). Similarly, depletion of hnRNP
A1 (siRNA) in MCF-10A resulted in a significant increase of
FIGURE 3 |TERRA co-localization at telomeres. (A) 2D analysis of TERRA
and TRF2 foci. Merging of the green (TERRA) and red (TRF2/telomeres)
channels denotes potentially co-localized foci as yellow signals. (B) 3D
analysis of TERRA and TRF2 foci. Deconvolution and 3D reconstruction of
22 stacks per cell nuclei provided a high-resolution perspective of TERRA
co-localization at individual telomeres. Navigation of the 3D image provided
a defined representation of telomere location throughout the cell nucleus,
as well as TERRA distribution; i.e., either bound (co-localized with telomere)
or free (not co-localized with telomere). Scale bar=8 microns.
TERRA foci compared to the control (mock): total number of foci
increased from 1960 to 2264; average foci per cell increased from
49 to 57 (p= 0.0004). In MCF-7, inhibition of DNA-PKcs kinase
activity (NU) resulted in a significant increase of TERRA foci
compared to the control (DMSO): total number of foci increased
from 1927 to 2013; average foci per cell increased from 48 to 50
(p= 0.029). Depletion of hnRNP A1 (siRNA) in MCF-7 resulted
in a significant increase of TERRA foci compared to the mock
control: total number of foci increased from 1830 to 2082; average
foci per cell increased from 46 to 52 (p= 0.031).
Comparison of the total number of TERRA foci (co-
localized/bound and free) in MCF-10A and MCF-7 untreated
controls (DMSO and mock) also revealed a statistically signifi-
cant higher number of TERRA foci in MCF-10A (3935) than in
MCF-7 (3757); average number of TERRA foci per cell being 49
and 46 respectively. In both treatment groups, MCF-7 also had
fewer TERRA foci than MCF-10A (NU: 2013 vs. 2237; siRNA:
2082 vs. 2264). RNA dot blot analysis of total TERRA levels in
unsynchronized MCF-10A and MCF-7 cells demonstrated that
overall levels of TERRA were not significantly different between
the two cell lines, and further that TERRA levels were not sig-
nificantly affected by either DNA-PKcs kinase inhibition (NU)
or depletion of hnRNP A1 (siRNA) compared to untreated and
DMSO controls (Figure 6). The underlying reason for overall
fewer total TERRA foci in MCF-7 compared to MCF-10A remains
undetermined.
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FIGURE 4 |Total number of co-localizedTRF2/TERRA foci. Experimental
groups consisted of: control (DMSO) and DNA-PK inhibitor (NU7026);
control (mock) and hnRNP A1 depleted (siRNA). (A) In MCF-10A,
statistically significant increases in co-localization of TERRA at telomeres
(TRF2) were observed for both NU7026 and siRNA treatments (*p<0.05).
(B) In MCF-7, no statistically significant differences in co-localization of
TERRA at telomeres (TRF2) were observed for either NU7026 or siRNA
treatment (p>0.05). Data are±SEM for n=40 TERRA positive cells.
FIGURE 5 |Total number ofTERRA foci (bound and free). Experimental
groups consisted of: control (DMSO) and DNA-PK inhibitor (NU7026);
control (mock) and hnRNP A1 depleted (siRNA). (A) In MCF-10A,
statistically significant increases in the total number of TERRA foci were
observed for both NU7026 and siRNA treatments (*p<0.05). (B)
Statistically significant increases in the total number of TERRA foci were
also observed in MCF-7 for both treatments (*p<0.05). Data are±SEM for
n=40 TERRA positive cells.
FRAGILE TELOMERES ARE INCREASED WITH DEPLETION OF hnRNP A1
To investigate whether hTR/DNA-PKcs and hnRNP A1 interac-
tions influenced efficient telomere replication and end-capping,
we analyzed a variety of telomere dysfunction endpoints including
fragile telomeres, as well as conventional chromosome aberra-
tions following siRNA depletion of hnRNP A1. Standard telomere
FISH analysis revealed significantly elevated frequencies of frag-
ile telomeres, defined as extended (“stringy”) individual telomere
signals, or as two distinct telomere signals on the same chromatid
(doublets), in both MCF-10A and MCF-7 (Figure 7). Fragile
telomere frequencies per cell were: MCF-10A UT 0.867, mock
1.044, siRNA 1.644, p< 0.01; and MCF-7 UT 1.778, mock 1.622,
siRNA 3.60,p< 0.01. Two-color Chromosome-Orientation (CO)-
FISH strategies (Bailey et al., 2004c, 2010) were also employed
to evaluate potential strand-specificity for the incidence of frag-
ile telomeres upon hnRNP A1 depletion, however no significant
preference for leading- vs. lagging-strand was evident (p> 0,05;
data not shown). Telomere signal free ends (SFEs) were also mon-
itored, but no significant differences were seen (data not shown).
Additionally, telomere sister chromatid exchange (T-SCE; Bailey
et al., 2004a) frequencies were examined and no significant dif-
ferences were observed (data not shown). There were also no
significant increases in telomere fusion, or any chromosome or
chromatid-type aberrations. Together, these results further sup-
port hTR/DNA-PKcs and hnRNP A1 participation in TERRA
removal from telomeres facilitating efficient telomere replication
and maintaining telomere stability.
DISCUSSION
Intrigued by the demonstrations of hnRNP A1 phosphorylation
by DNA-PKcs, a post-translational modification shown to be stim-
ulated by the RNA template component of human telomerase hTR
(Zhang et al., 2004; Ting et al., 2009),we investigated potential roles
of hTR/DNA-PKcs dependent phosphorylation of hnRNP A1 in
human telomeric end-capping structure and function involving
telomeric RNA (TERRA) distribution at telomeres. Interestingly,
evaluation of co-localized foci utilizing 3D reconstruction strate-
gies revealed a highly conserved orientation of telomeres/TRF2
and TERRA, an observation conceivably consistent with reports
of non-random organization of mammalian telomeres (Chuang
et al., 2004), telomere attachment to fixed subnuclear structures
(de Lange, 1992), and/or constrained telomere movement (Wang
et al., 2008).
Increased recombination at common fragile sites has been
reported (Glover and Stein, 1987; Feichtinger and Schmid, 1989),
and although telomeres do not exactly fit the classic definition
of common chromosomal fragile sites (Le Beau, 1986; Suther-
land and Richards, 1995), they do exhibit features of rare fragile
sites in that they experience instability under replication stress.
We found that both inhibition of DNA-PKcs kinase activity and
siRNA depletion of hnRNP A1 resulted in significant accumula-
tion of TERRA at individual telomeres, and further that depletion
of hnRNP A1 increased frequencies of fragile telomeres. These
observations are consistent with previous demonstrations that
decreased levels of the nonsense RNA-mediated decay (NMD) fac-
tors SMG1 and UPF1 increased TERRA localization at telomeres
(Azzalin et al., 2007) and interfered with replication of leading-
strand telomeres (Chawla et al., 2011). However, no strand-
specificity for fragile telomeres was observed upon loss of hnRNP
A1, suggesting that hnRNP A1 operates at all telomeres to facilitate
efficient telomere replication.
It is noteworthy that in both MCF-10A and MCF-7 under
conditions of decreased DNA-PKcs and decreased hnRNP A1
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FIGURE 6 |TotalTERRA levels. Total RNA from unsynchronized cells
was extracted and TERRA probed by dot blot and normalized to GAPDH
(control). RNase treatment confirmed probe specificity for RNA.
Comparisons examined for statistical analyses were: DNA-PKcs kinase
inhibition (NU) vs. untreated (UT) and DMSO controls; or hnRNP A1
depletion (siRNA) vs. untreated (UT2) and mock controls. (A) Total
levels of TERRA in MCF-10A were not significantly affected by either
treatment (p>0.05). (B) Total levels of TERRA in MCF-7 were not
significantly affected by either treatment (p>0.05). Data are±SEM:
for n=3.
phosphorylation, 30–60% of hnRNP A1 remained phosphory-
lated, most likely reflecting other protein kinases playing a role as
previously proposed (Ting et al., 2009). Potential candidates for
phosphorylating hnRNP A1 include protein kinase A, p38 MAP
Kinase, protein kinase C, and casein kinase (Cobianchi et al., 1993;
Municio et al., 1995; Gao et al., 2000; Shimada et al., 2009). Fur-
ther, DNA-PKcs and ATM share many phosphorylation targets,
including γ-H2AX (Wang et al., 2005) and Replication Protein A
(RPA) (Brush et al., 1994, 1996; Boubnov and Weaver, 1995; Gately
et al., 1998). Indeed, less phosphorylated hnRNP A1 remained fol-
lowing depletion of DNA-PKcs (siRNA; 30–45%) compared to
DNA-PKcs kinase inhibition (NU; 60–100%), consistent with the
observation that siRNA knockdown of DNA-PKcs also reduces
ATM levels (Peng et al., 2005).
The dramatically different levels of hTR in MCF-10A vs. MCF-
7 cell lines (Ramachandran et al., 2002) influenced observed
DNA-PKcs mediated hnRNP A1 phosphorylation and TERRA co-
localization at telomeres. We demonstrated that diminution of
either DNA-PKcs kinase activity or hnRNP A1 levels in MCF-10A
resulted in TERRA remaining at, or accumulating on telomeres,
suggesting that hTR stimulation of DNA-PKcs phosphorylation
of hnRNP A1 is sufficient in MCF-10A to help regulate TERRA
distribution at telomeres. The observed lack of significant effect
of inhibiting DNA-PKcs kinase activity or depleting hnRNP A1
on co-localization of TERRA at telomeres in MCF-7 is consistent
with the considerably higher levels of hTR in MCF-7 as compared
to MCF-10A, as hTR not only stimulates DNA-PKcs dependent
phosphorylation of hnRNP A1 (Ting et al., 2009), hTR also asso-
ciates with TERRA (Schoeftner and Blasco, 2008). The high levels
of hTR in MCF-7 likely act to sequester TERRA, limiting its avail-
ability for co-localization to telomeres; thus depletion of hnRNP
A1 and reduced ability to remove TERRA from telomeres had lit-
tle effect. Such a scenario would also result in less available “free”
hTR for stimulation of DNA-PKcs and subsequent phosphoryla-
tion of hnRNP A1; thus inhibiting DNA-PKcs kinase activity had
little effect. Together, these results support hTR, DNA-PKcs, and
hnRNP A1 levels and interactions influencing TERRA distribution
on telomeres.
The observation of fewer total TERRA foci in MCF-7 than
in MCF-10A was somewhat surprising considering that MCF-7
has considerably more chromosomes than MCF-10A (2N = 48
vs. 66–88), however decreased TERRA has been reported in can-
cer (Schoeftner and Blasco, 2008), suggestive of disrupted TERRA
regulation. Therefore these results could reflect differences in
TERRA degradation, and/or the faster cell cycle time for MCF-7
compared to MCF-10A and the variation of TERRA levels with
phase of the cell cycle (Porro et al., 2010; Flynn et al., 2011).
However, the majority of cells scored here were presumed to
be in G1/early-to-mid S-phase, when TERRA levels are highest
and TERRA foci most obvious; cells without obvious TERRA
foci were not scored. When taken together with our observa-
tions of no change in co-localization of TERRA at telomeres
(bound fraction) in MCF-7 with either treatment (Figure 4B),
the increase of total TERRA foci in MCF-7 with both treat-
ments reflects increases in the free (not co-localized/bound)
fraction of TERRA. This finding is consistent with the high lev-
els of hTR in MCF-7 acting to hinder TERRA association with
telomeres.
www.frontiersin.org April 2013 | Volume 3 | Article 91 | 7
Le et al. TERRA, hnRNP A1, DNA-PKcs, and telomeres
FIGURE 7 | Fragile telomere frequencies are increased with
depletion of hnRNP A1. (A) Standard telomere FISH analysis revealed
significantly elevated frequencies of fragile telomeres (arrows).
(B) Two-color telomere CO-FISH was employed to evaluate
strand-specificity of fragile telomeres, however no significant preference
for leading- vs. lagging-strand fragile telomeres was observed (p>0.05;
data not shown). (C) Induced fragile telomere frequencies per cell and
per chromosome in both MCF-10A and MCF-7 were significantly elevated
following hnRNP A1 depletion (siRNA) as compared to mock controls
(**p<0.01).
It was also informative to consider the overall frequencies of
TRF2 (telomeres), TERRA, and co-localized foci (Figure 8) as
determined by our 3D reconstructions, as it became readily appar-
ent that although DNA-PKcs kinase inhibition and depletion of
hnRNP A1 resulted in variation, TERRA foci represented roughly
half the number of telomeric foci. Moreover, of the TERRA
that was present, about half was co-localized to telomeres (i.e.,
“bound”), indicating the other∼half was “free” (i.e., not “bound”
to telomeres). Additionally, ∼25% of the telomeres had TERRA
co-localized, consistent with not all telomeres having TERRA asso-
ciated with them. Therefore, our results suggest that the ratio or
balance of free to telomere-bound TERRA is influenced by hTR,
DNA-PKcs, and hnRNP A1 interactions.
Since hnRNP A1 associates with telomeric DNA and can inter-
act with both telomeric RNA (TERRA) (de Silanes et al., 2010)
and telomerase RNA (hTR) (Fiset and Chabot, 2001), we suggest
a model in which hTR stimulated DNA-PKcs phosphorylation of
hnRNP A1 serves to promote removal of “bound” TERRA from
telomeres (Figure 9). It was recently proposed that TERRA shut-
tles hnRNP A1 off telomeres to facilitate a RPA-to-POT1 switch
on single-stranded telomeric DNA after replication to facilitate
end-capping (Flynn et al., 2011). We propose that hnRNP A1 may
also shuttle TERRA off telomeres to facilitate efficient replication.
Due to sequence complementarity, it may be especially important
to remove TERRA from leading-strand telomeres and/or degrade
TERRA sufficiently via UPF1 and the NMD pathway to promote
S-phase progression. As TERRA is also complementary to hTR,
it is also possible that hnRNP A1 participates in recruitment of
free hTR to its 3′ single-stranded overhang/substrate on lagging-
strand telomeres. Such interactions at telomeres, although requir-
ing further examination, begin to address potential strand-specific
differences between leading- vs. lagging-strand telomeres, which
may serve to promote and/or complete their particular replica-
tion and/or extension, as well as their processing for generation of
terminal single-stranded overhangs.
Lastly, we speculate that TERRA sequestration by hTR hin-
ders TERRA localization to telomeres, such that the balance of
free to telomere-bound TERRA is influenced by hTR. Likewise,
the balance of free hTR to that associated with TERRA influences
DNA-PKcs and hnRNP A1 interactions. In G1-phase for example,
when TERRA levels are high, much of the hTR would be associated
with TERRA. In S-phase, as TERRA levels diminish, more hTR
would become available for stimulation of DNA-PKcs and site-
specific hnRNP A1 phosphorylation, as well as for recruitment to
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FIGURE 8 | Frequencies ofTRF2,TERRA, and co-localized foci in MCF-10A
and MCF-7. 3D reconstruction and analysis of co-localization facilitated
distinction between bound TERRA (TERRA foci co-localized at
telomeres=dark blue bar), and free TERRA (difference between total TERRA
foci=gray bar and co-localized/bound TERRA=dark blue bar). Number of
telomere foci are normalized to 1.00 (light blue bar). Overall relationships are
maintained, but the balance of free to bound TERRA is influenced by hTR,
DNA-PKcs, and hnRNP A1 interactions.
telomeric single-stranded overhangs. We propose that DNA-PKcs
and hnRNP A1 interactions are driven by hTR and TERRA asso-
ciations, which ultimately serve to promote removal of telomere-
bound TERRA, contributing to S-phase progression and efficient
telomere replication.
Our contemporary view and appreciation of telomeres is far
removed from the days of these deceptively simple terminal fea-
tures being regarded as “junk” DNA. Although telomeres are
strictly limited in sequence, restricted to location and constrained
in movement, they provide chromosomal end-structure and func-
tion critical to maintaining genomic integrity and stability. That
telomeres are transcribed is remarkable in and of itself, but TERRA
also introduces a plethora of novel mechanisms not only for its
own and telomere regulation, but for the regulation of the myriad
of telomere interacting partners as well. Telomeric coordination
of replication, transcription, and repression of repair is nothing
short of extraordinary.
MATERIALS AND METHODS
CELL CULTURE
The human mammary epithelial non-tumorigenic cell line, MCF-
10A, was purchased from ATCC and cultured in 1:1 Dul-
becco’s Modified Eagle’s Medium (DMEM)/Ham’s F12 growth
media (Hyclone) supplemented with 5% FBS, 20 ng/ml Epidermal
Growth Factor (EGF; Sigma), 0.5µg/ml hydrocortisone (Sigma),
0.1µg/ml cholera toxin (Sigma), 10µg/ml insulin (Sigma), 1%
Glutamax (Life Technologies) and 1% penicillin/streptomycin
(Hyclone). The MCF-7 cell line (gift from L. Chubb, CSU Animal
Cancer Center), originally derived from a human breast adenocar-
cinoma, was grown in Minimum Essential Media/Earle’s Balanced
Salt Solution (MEM/EBSS; Hyclone) media supplemented with
10% fetal bovine serum (FBS; Sigma). Cells were grown at 37˚C
in a humidified incubator with 5% CO2 and passaged 1–2 times
per week.
TRANSFECTIONS AND TREATMENTS
For small interfering RNA (siRNA) knockdowns, reverse trans-
fection was performed as recommended by the Lipofectamine
RNAimax manufacturer (Life Technologies). Cells were seeded
at∼50% confluency and treated with lipofectamine alone (mock)
or with lipofectamine and siRNA oligonucleotide (treated); an
untreated (UT) control was also included. For targeting of
DNA-PKcs, cells were incubated with custom designed siRNAs:
sense sequence GAUCGCACCUUACUCUGUUdTdT; antisense
sequence AACAGAGUAAGGUGCGAUCdTdT (Dharmacon), at
a final concentration of 25 nM as previously described (Peng
et al., 2002). For targeting of hnRNP A1, cells were incu-
bated with the ON-TARGET plus SMARTpool siRNA (Dhar-
macon) at a final concentration of 10 nM. Oligo sequences
included: CGGAAACCUUGGUGUAGUU; GGGAAUGAAGCU-
UGUGUAU; CAACUUCGGUCGUGGAGGA; and UAGAAUUC-
CUUCAGGGUGA. Cells were collected at various time points
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FIGURE 9 | Speculative model ofTERRA, hnRNP A1, and
hTR/DNA-PKcs interactions at telomeres. The presence of “free” hTR
(not associated with TERRA) stimulates DNA-PKcs phosphorylation of
hnRNP A1, an event that contributes to the removal of TERRA from
telomeres and may be especially important at leading-strand telomeres due
to sequence complementary with TERRA. hnRNP A1 shuttling of TERRA off
telomeres and out of the nucleus to the cytoplasm may aid the NMD
pathway of TERRA degradation and serve to regulate TERRA levels in a cell
cycle dependent manner. This supposition is supported by previous
demonstrations of SMG1 stimulation and UPF1 action at leading-strand
telomeres (Chawla et al., 2011). As TERRA is also complementary to hTR,
when TERRA levels are low in S-phase, hnRNP A1 may also aid in the
recruitment of hTR to its 3′ single-stranded overhang/substrate on newly
replicated lagging-strand telomeres. When TERRA levels are high (e.g., in
G1), sequestration of hTR by TERRA limits TERRA localization to telomeres,
and influences the balance of free to telomere-bound TERRA.
following transfection and knockdown efficiencies were evaluated
by real-time Polymerase Chain Reaction (PCR) and immunoblot
analysis. Optimal knockdown of DNA-PKcs and hnRNP A1 in
both cell lines (∼90%) was achieved at 72 h, which was subse-
quently used for all experiments. Four experimental harvests were
performed (n= 4) and each was examined with two immunoblot
analyses.
For DNA-PKcs kinase activity inhibition, cells were treated with
the specific DNA-PKcs kinase activity inhibitor 2-(Morpholin-
4-yl)-benzo[h]chromen-4-one (NU7026; Sigma) solubilized in
Dimethyl Sulfoxide (DMSO) at a final concentration of 10µM
(v/v 0.1% DMSO). A DMSO control was also included. Cells were
incubated for 24 h at 37˚C.
CELL LYSIS, PROTEIN QUANTIFICATION, AND IMMUNOBLOTTING
MCF-10A and MCF-7 cell pellets were washed in phosphate
buffered saline (PBS) and incubated in lysis buffer for 10 min on
ice with periodic mixing. Lysis buffer included 50 mM Tris-HCL,
150 mM NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA),
2 mM ethylene glycol tetraacetic acid (EGTA), 25 mM sodium
fluoride, 25 mM β-glycerophosphate, 0.2% Triton X-100, 0.3%
NP-40, and 0.1 mM sodium orthovanadate in water. Protease
inhibitors were added directly before use, including 0.1 mM
phenylmethylsulfonyl fluoride (PMSF), 5µg/ml leupeptin, and
5µg/ml aprotinin. For phosphorylation experiments, cells were
rinsed with PBS, and lysis buffer with Halt phosphatase inhibitors
(Pierce) was added directly to the tissue culture flask for 10 min
on ice. The Bradford Assay was used to quantify total protein
amounts (Bio-Rad). For immunoblots, protein samples were sep-
arated via Sodium Dodecyl Sulfate Solution Polyacrylamide Gel
Electrophoresis (SDS-PAGE) and transferred to a methanol acti-
vated polyvinylidene fluoride (PVDF) membrane. The membrane
was blocked for 1 h with 4% powdered milk in Tris-buffered saline
with 0.1% Tween (TBST) at room temperature, with rotation, and
rinsed once in TBST before incubating with primary antibody
in 1% milk in TBST for 1 h at room temperature or overnight at
4˚C with shaking. Primary antibody dilutions included hnRNP A1
(Abcam ab5832 clone 9H10) at a 1:1000 concentration, β-tubulin
(Abcam ab6046) at a 1:1000 concentration,DNA-PKcs (NeoMark-
ers MS-423-P) at a 1:40 concentration and Actin (Abcam Ab3280)
at 1:1000. The membrane was subsequently washed 4 times in 1X
TBST for 5 min each at room temperature with shaking, incubated
with secondary antibody in Licor Blocking Buffer (Odyssey) for
2 h at room temperature with shaking and then washed in TBST
washes as above. Alexa Fluor 680 (Invitrogen A21058) and goat
anti-rabbit IgG 800 (Thermo Scientific 35571) secondary anti-
bodies were added at a 1:10,000 and 1:40,000 dilution respectively.
Lastly, the membrane was imaged on the Odyssey Imaging System
(Licor). Relative protein expression was measured as a ratio of the
intensity of the treatment bands to the housekeeping band using
Odyssey imaging software and accounting for background.
PHOSPHORUS-32 (32P) UPTAKE ASSAY FOR hnRNP A1
PHOSPHORYLATION STATUS
MCF-10A and MCF-7 cells were rinsed once and incubated
with phosphate-free media Dulbecco’s Minimum Essential Media
(DMEM; Invitrogen) for 24 h to deplete adenosine triphosphate
(ATP) pools. 400µCi of 32P (orthophosphate; Perkin Elmer) per
2 ml of media was added and incubated at 37˚C for 4 h to allow
for labeling of ATP pools, as previously described (Ting et al.,
2009). Cells were subsequently lysed and total protein amount
quantified via Bradford assay, followed by immunoprecipitation of
hnRNP A1 and Sodium Dodecyl Sulfate Solution Polyacrylamide
Gel Electrophoresis (SDS-PAGE). Phosphorylation of hnRNP A1
was quantified per sample as the ratio of 32P signal to hnRNP A1
(i.e., in the same lane).
IMMUNOPRECIPITATION OF hnRNP A1 AND SDS-PAGE
Immunoprecipitations were performed using the Direct IP kit
(Pierce) as recommended by the manufacturer. Whole cell lysates
were pre-cleared by incubating with control resin for 30 min with
rocking. Approximately, 1000µg of protein was incubated with
50µg of antibody against hnRNP A1 (Abcam ab5832 clone 9H10)
or IgG control (R&D Systems MAB004) for 1 h with rotation
at room temperature. Samples were acetone precipitated, sub-
sequently examined by SDS-PAGE and transferred to a PVDF
membrane using a semi-dry transfer method performed at 15 V
for 1.25 h. Membranes were exposed to a phosphor imaging screen
(Kodak) for 48 h, which was imaged on a Storm 860 (GE Health-
care Life Sciences) and quantified using Image Quant (GE Health-
care Life Sciences) software. The same membrane was rewet and
probed for total amounts of hnRNP A1 via immunoblotting (see
Cell Lysis, Protein Quantification, and Immunoblotting).
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QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Total RNA was harvested from untreated, mock treated, and
siRNA treated samples using the Qiagen RNeasy kit (Qiagen).
RNA was quantified using a Nanodrop spectrophotometer and
reverse transcribed using the Verso cDNA kit (Thermo Scien-
tific). Real-time PCR was performed using SYBR green (Thermo
Scientific) according to manufacturer’s protocol and performed
using a Bio-Rad iCycler IQ. The real-time cycle was as fol-
lows: Cycle 1 at 95˚C for 15 min, cycle 2 (40×) step 1 at 95˚C
for 15 s, step 2 at 59˚C for 30 s, and step 3 at 72˚C for 30 s.
A melt curve was included to assess primer dimers and non-
specific amplification as follows: cycle 3 at 95˚C for 30 s, cycle
4 at 55˚C for 30 s, and cycle 5 (80×) at 55˚C for 10 s. Primers
for amplification of human DNA-PKcs (Sigma) were added at a
final concentration of 300 nM: forward sequence AGCAATGCAC-
CGTTGTGGT; reverse sequence TCCTTCTTCAGGAGCTTCCA.
Primers for amplification of transferrin receptor (TFRC) (Sigma)
at a final concentration of 300 nM were included as a house-
keeping gene: forward sequence CGCTGGTCAGTTCGTGATTA;
reverse sequence GCATTCCCGAAATCTGTTGT. Relative DNA-
PKcs mRNA expression was analyzed using the 2−∆∆CT method.
RNA-FLUORESCENCE IN SITU HYBRIDIZATION AND
IMMUNOCYTOCHEMISTRY
Cells were grown on chamber slides, then washed with cytoskele-
ton (CSK) buffer for 30 s, fixed in 3% paraformaldehyde for 10 min
and permeabilized with 0.5% Triton X-100 in CSK/vanadyl for
5 min. Following permeabilization, slides were blocked with 3%
bovine serum albumin (BSA) for 1 h, then incubated for 1 h with
mouse anti-telomere repeat factor 2 (TRF2) primary antibody
(Imgenex; San Diego, CA, USA) followed by incubation with anti-
mouse AlexaFluor-594 secondary antibody (Life Technologies) for
45 min. Slides were washed once with 1×PBS, incubated overnight
with a FITC labeled peptide nucleic acid (PNA) (Bio-Synthesis Inc,
Lewisville, TX, USA) telomere probe (CCCTAA)7 complemen-
tary to TERRA and sequentially washed in 50% formamide/2×
saline sodium citrate (SSC), 2× SSC, and 2× SSC/NP-40 at 39˚C
for 2.3 min each. Lastly, the slides were mounted with ProLong
Gold Antifade with 4′,6-diamidino-2-phenylindole dihydrochlo-
ride (DAPI; Life Technologies).
MICROSCOPY AND IMAGING
Images were acquired and analyzed using a Zeiss Axio Imager.Z2
epi-fluorescent microscope running Metamorph software (Mol-
ecular Devices). For each cell, 22-stacked images taken at
0.2µm intervals, per channel, were obtained with a 1.25
numerical aperture 100× oil immersion objective then ana-
lyzed by 3D deconvolution and reconstruction. ImageJ software
(http://rsb.info.nih.gov./ij/) and JACoP plugin (National Institute
of Health; NIH) were used to evaluate co-localization of TRF2
(telomeres) and TERRA foci from 3D images in the red channel
for TRF2 (anti-mouse AlexaFluor-594; Life Technologies) and the
green channel for TERRA (FITC labeled PNA probe; Bio-Synthesis
Inc, Lewisville, TX, USA). Several co-localization coefficients such
as Pearson’s, Mander’s, and Overlap were calculated using the
ImageJ and JACoP plugin, to assess the degree of signal co-
localization in the 3D images and generate co-localization profiles
for each individual cell. Additionally, ImageJ software was utilized
for co-localization foci counts and evaluation of the foci numbers.
Costes randomization was used to exclude any co-localization of
pixels that might have occurred due to chance (Bolte and Corde-
lieres, 2006). For each condition, 40 TERRA positive cells were
imaged (n= 40).
RNA DOT BLOT
RNA dot blots were performed as previously described with some
modifications (Kafatos et al., 1979). Total RNA was extracted using
a Qiagen RNeasy kit (Qiagen), and RNA quality was assessed
by gel electrophoresis. GeneScreen Plus Nylon (Perkin Elmer)
and Bio-Dot SF filter paper (Bio-Rad) were pre-wet in 20×
SSC and assembled into a Bio-Rad Bio-Dot apparatus attached
to a vacuum source. The membrane was rinsed twice in 10×
SSC. About 7.5µg of RNA was suspended in RNA denaturing
solution [66% formamide, 21% Formaldehyde (37%), 13% 10×
MOPs pH 7] and denatured for 5 min at 75˚C. Equal volumes
of 20× SSC were added. Samples were subsequently applied to
the Bio-Dot apparatus and washed twice with 10× SSC. Vac-
uum was applied to dry the membrane. The membrane was
then removed and placed in a UV Stratalinker 2400 (Strata-
gene) equipped with 254 nm bulbs for 25–50 s. The membrane
was stained in 0.02% Methylene blue, 0.5 M Sodium Acetate, pH
5.2 in order to visualize and mark RNA dots. The membrane
was then incubated in hybridization solution [2 mM vanadyl,
50% formamide, 30% 20× SSC, 1% 50× Denhardt’s solution,
0.25% SDS (20%), 0.1% or 250µg/ml salmon sperm DNA,
brought up to volume with ddH20] for 2 h at 42˚C. Next, the
membrane was incubated with fresh hybridization buffer con-
taining denatured PNA FITC labeled TERRA probe (CCCTAA)7
and FITC labeled-GAPDH PNA probe (DAKO) overnight at
42˚C. Following incubation, the membrane was washed with
shaking: (1) four times in 2× SSC at room temperature for
10 min each; (2) two times in 0.1× SSC 2, 0.1% SDS at 50˚C
for 30 min each; and (3) two times in 0.1× SSC, 0.5% SDS
at 68˚C for 30 min each. Membrane imaging was performed
on a Storm 860 (GE Healthcare) and analysis was done using
ImageJ software. Three experimental harvests were dot blotted
and analyzed (n= 3).
FLUORESCENCE IN SITU HYBRIDIZATION AND TWO-COLOR
CHROMOSOME-ORIENTATION FISH
Metaphase spreads were collected using standard cytogenetic tech-
niques (Henegariu et al., 2001). Briefly, cells were incubated
with 0.1µg/ml colcemid, harvested and lysed with 75 mM KCL,
fixed in 3:1 methanol: acetic acid and added to pre-cleaned
slides. Slides were fixed in 3% paraformaldehyde, dehydrated
through an ethanol series (75, 85, and 100%) and denatured
in 70% formamide/2× saline sodium citrate (SSC) at 70˚C for
2 min. For standard FISH, a G-rich telomere Peptide Nucleic
Acid (PNA) probe (TTAGGG)7 labeled with Cy-3 (Bio-Synthesis
Inc; Lewisville, TX, USA) was hybridized onto the slides at 37˚C
for 30–60 min. For two color CO-FISH, the C-rich telomere
probe (CCCTAA)7 labeled with FITC was also hybridized onto
the slide at 37˚C overnight. Slides were then washed in 50%
formamide/2×SSC, 2× SSC, and 0.1% NP-40/2× SSC at 43˚C for
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2.5 min each. Lastly, slides were mounted in Prolong Gold Antifade
(Life Technologies) with DAPI.
CO-FISH methodology has been described previously (Bailey
et al., 2010) and was used here with modification. Cells were incu-
bated for a single round of replication in 5-bromo-2′-deoxyuridine
and 5-bromo-2′-deoxy-cytosine (BrdU/BrdC) at a 3:1 ratio for
a final concentration of 5× 10−5 M. Prior to denaturing, slides
were stained with Hoechst 33258 (0.5µg/ml), exposed to Ultravi-
olet (UV) light in a Stratalinker outfitted with 365 nm bulbs for
35 min, then incubated with Exonuclease III (∼10 U) for 20 min
at 25˚C. Lastly, slides were hybridized with telomere probes as
described above. For FISH and CO-FISH analyses, three indepen-
dent experiments (n= 3) were performed and 30 metaphases were
scored per experiment. The individual experiments were averaged
for statistical analysis.
CHROMOSOME AND TELOMERE ABERRATION SCORING CRITERIA
Chromosome aberrations were scored as classically defined. Clonal
chromosome-type aberrations were not included in the final
analysis, as our intent was to evaluate induced aberration fre-
quencies. Chromatid-type gaps were defined as discontinuities in
DAPI staining less than the width of a chromatid arm. Chromatid-
type breaks were defined as a discontinuity in DAPI equal to or
greater than the width of a chromatid. Telomere function was eval-
uated using several endpoints. Fragile telomeres were defined as
one extended telomere signal (i.e., “stringy”) and/or duplicated
telomere signals on the same sister chromatid within one signal
width of one another. Telomere signals that did not meet these
criteria were scored as interstitial telomere signals (ITS) and were
not included as a “fragile” telomere. Signal free ends (SFE) were
assessed following both FISH and CO-FISH using two different
scoring criteria. First, SFEs were scored as a complete lack of telom-
ere signal on one chromatid arm. Secondly, SFEs were scored as a
single event only if the signal was missing from both sister chro-
matid arms, as would be expected with telomere shortening and
subsequent replication. T-SCE were scored as a CO-FISH telomere
signal split between the two sister chromatids. Telomere fusion was
defined as two telomere signals merged into one at chromosome
or chromatid rearrangement breakpoints.
STATISTICAL ANALYSIS
Experimental output for siRNA knockdowns were statistically ana-
lyzed using student t -test via GraphPad Prism statistical software
(v5.0, La Jolla, CA, USA). All other statistical analyses were per-
formed using SAS (SAS Institute Inc., Cary, NC, USA) and the
Simple Differences Least Squares Means model to determine sta-
tistically significant trends in the data. All data is represented as the
mean± SEM. A p-value <0.05 was considered to be statistically
significant.
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